CPIX
Cumberland Pharmaceuticals Inc.
CPIX's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over CPIX overall, supported by stronger fundamentals and lower modeled downside.
CPIX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
CPIX's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CPIX PE Valuation
CPIX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CPIX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CPIX's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CPIX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.73 | -$0.51 |
| Q1 2026 | -$0.49 | -$0.24 |
| Q4 2025 | -$0.19 | +$0.28 |
| Q3 2025 | -$0.24 | +$0.53 |
| Q2 2025 | -$0.22 | +$0.51 |
| Q1 2025 | -$0.25 | +$0.34 |
| Q4 2024 | -$0.47 | -$0.03 |
| Q3 2024 | -$0.77 | -$0.60 |
CPIX lost $0.73 per share over the past year, a bigger loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CPIX on earnings quality, reporting a profit while its opponent remains loss making.
CPIX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.8M | -19% |
| Q1 2026 | $9.1M | -22% |
| Q4 2025 | $13.7M | +31% |
| Q3 2025 | $8.3M | -8.7% |
| Q2 2025 | $10.8M | +10% |
| Q1 2025 | $11.7M | +38% |
| Q4 2024 | $10.4M | +12% |
| Q3 2024 | $9.1M | -9.9% |
CPIX's revenue is shrinking: $9M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -36% | -29 points |
| Q1 2026 | -34% | -45 points |
| Q4 2025 | -10% | +7.6 points |
| Q3 2025 | -24% | -5.1 points |
| Q2 2025 | -6.9% | +3.5 points |
| Q1 2025 | 11% | +33 points |
| Q4 2024 | -18% | +48 points |
| Q3 2024 | -19% | -0.1 points |
CPIX's operating margin was −36% last quarter, down 29 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CPIX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CPIX on profitability, with a higher operating margin.
CPIX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $130.5K | -84% |
| Q1 2026 | $387K | -90% |
| Q4 2025 | $3K | -100% |
| Q3 2025 | $163.4K | -64% |
| Q2 2025 | $817.3K | +$1.7M |
| Q1 2025 | $3.9M | +$6M |
| Q4 2024 | $1.9M | +92% |
| Q3 2024 | $460.1K | -61% |
CPIX still generates free cash flow, though less than at its 2023 peak: $683,899 over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CPIX on cash flow, with more consistent year-over-year improvement.
CPIX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +21.4K shares |
| 1 year | +0.1% | +21K shares |
| 3 years | +2.9% | +427K shares |
| 5 years | -0.8% | -128K shares |
| Available history | -2.5% | -386K shares |
CPIX has 15M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | $61,001 |
| Q4 2025 | — |
| Q3 2025 | $10,439 |
| Q2 2025 | $7,171 |
| Q1 2025 | $245,868 |
| Q4 2024 | $98,383 |
| Q3 2024 | $98,815 |
CPIX has spent almost nothing on buybacks in the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CPIX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CPIX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -4.6x | Net Cash |
| Q3 2025 | -7.5x | Net Cash |
| Q2 2025 | -6.4x | Net Cash |
| Q1 2025 | -6.5x | Net Cash |
| Q2 2023 | -11.7x | Net Cash |
| Q4 2019 | -12.4x | Net Cash |
CPIX has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CPIX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.4 | Neutral |
| Stochastic | 26.9 | Neutral |
CPIX's weekly RSI is 51 (neutral) and its Stochastic is 27 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CPIX PE vs Healthcare Sector
CPIX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CPIX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.78 | 2.2% below |
| 20 week MA | $6.94 | 4.5% below |
| 50 week MA | $5.33 | 24% above |
| 100 week MA | $4.51 | 47% above |
| 200 week MA | $3.12 | 113% above |
CPIX has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 113% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CPIX on trend strength, trading above more of its moving averages.
CPIX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.14 | $3.06 | -40% |
| 2021 | $3.06 | $5.12 | +67% |
| 2022 | $5.12 | $2.11 | -59% |
| 2023 | $2.11 | $1.79 | -15% |
| 2024 | $1.79 | $2.32 | +30% |
| 2025 | $2.32 | $4.12 | +78% |
| 2026 YTD | $4.12 | $6.63 | +61% |
CPIX has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.